<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39340058</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>08</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Effectiveness of EV-A71 Vaccine and Its Impact on the Incidence of Hand, Foot and Mouth Disease: A Systematic Review.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1028</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12091028</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Vaccination is a highly effective strategy for the prevention of enterovirus A71 (EV-A71)-hand, foot, and mouth disease (HFMD). Three inactivated EV-A71 vaccines in China have demonstrated remarkable efficacy against EV-A71-HFMD during clinical trials, exhibiting vaccine effectiveness (VE) exceeding 90% and few adverse events (AEs). However, the effectiveness of vaccines in the real world and its impact on the epidemiological characteristics of HFMD after the use of EV-A71 inactivated vaccine are uncertain.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The odd ratio (OR) and 95% confidence (CI) were used as the effect estimates of the meta-analysis in the test-negative design (TND), and the OR was used to calculate VE: VE = (1 - OR) × 100%.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">According to the literature search strategy, a comprehensive search was conducted in PubMed, Web of Science (including Chinese Science Citation Database and MEDLINE), and Embase, and 18 records were ultimately included in this study. Subsequently, the overall VE and 95% CI of different vaccine doses were analyzed, with the one-dose vaccine at 66.9% (95% CI: 45.2-80.0%) and the two-dose vaccine at 84.2% (95% CI: 79.4-87.9%). Additionally, the most reported AEs were mild general reactions without any rare occurrences. Simultaneously, the widespread use of the EV-A71 vaccine would lead to a reduction in both the incidence of EV-A71-associated HFMD and severe cases caused by EV-A71.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The administration of the two-dose EV-A71 vaccine is highly effective in preventing HFMD in the real world, and the widespread use of the EV-A71 vaccine leads to a reduction in the incidence of EV-A71-associated HFMD and that of severe cases caused by EV-A71. The findings suggest that administering the two-dose EV-A71 inactivated vaccine to children aged 6 months to 71 months can be effective in preventing EV-A71-associated HFMD, highlighting the need for developing a multivalent HFMD vaccine for preventing cases not caused by EV-A71.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Quanman</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>College of Public Health, Zhengzhou University, Zhengzhou 450001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Yaqi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>College of Public Health, Zhengzhou University, Zhengzhou 450001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ji</LastName><ForeName>Fucang</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Center for Disease Control and Prevention of Zhengyang, Zhengyang, Zhumadian 463600, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Fei</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>College of Public Health, Zhengzhou University, Zhengzhou 450001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Xiaoru</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>College of Public Health, Zhengzhou University, Zhengzhou 450001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Saiwei</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>College of Public Health, Zhengzhou University, Zhengzhou 450001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zijie</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0002-1860-1029</Identifier><AffiliationInfo><Affiliation>College of Public Health, Zhengzhou University, Zhengzhou 450001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geng</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>College of Public Health, Zhengzhou University, Zhengzhou 450001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Haiyan</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-1797-304X</Identifier><AffiliationInfo><Affiliation>College of Public Health, Zhengzhou University, Zhengzhou 450001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Long</LastName><ForeName>Jinzhao</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>College of Public Health, Zhengzhou University, Zhengzhou 450001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Yuefei</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-1523-0808</Identifier><AffiliationInfo><Affiliation>College of Public Health, Zhengzhou University, Zhengzhou 450001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Shuaiyin</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-6129-0310</Identifier><AffiliationInfo><Affiliation>College of Public Health, Zhengzhou University, Zhengzhou 450001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duan</LastName><ForeName>Guangcai</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>College of Public Health, Zhengzhou University, Zhengzhou 450001, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>82002147</GrantID><Agency>National Natural Science Foundation of China</Agency><Country /></Grant><Grant><GrantID>82273695</GrantID><Agency>National Natural Science Foundation of China</Agency><Country /></Grant><Grant><GrantID>82073618</GrantID><Agency>National Natural Science Foundation of China</Agency><Country /></Grant><Grant><GrantID>242102311147</GrantID><Agency>Henan Province Science and Technology Research Project</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">EV-A71 vaccine</Keyword><Keyword MajorTopicYN="N">HFMD</Keyword><Keyword MajorTopicYN="N">effectiveness</Keyword><Keyword MajorTopicYN="N">epidemiological characteristics</Keyword><Keyword MajorTopicYN="N">meta-analysis</Keyword><Keyword MajorTopicYN="N">test-negative design</Keyword></KeywordList><CoiStatement>All authors report that they have no potential conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39340058</ArticleId><ArticleId IdType="pmc">PMC11435758</ArticleId><ArticleId IdType="doi">10.3390/vaccines12091028</ArticleId><ArticleId IdType="pii">vaccines12091028</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Yang B., Liu F., Liao Q., Wu P., Chang Z., Huang J., Long L., Luo L., Li Y., Leung G.M., et al. Epidemiology of hand, foot and mouth disease in China, 2008 to 2015 prior to the introduction of EV-A71 vaccine. Euro. Surveill. 2017;22:16-00824. doi: 10.2807/1560-7917.ES.2017.22.50.16-00824.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2017.22.50.16-00824</ArticleId><ArticleId IdType="pmc">PMC5743100</ArticleId><ArticleId IdType="pubmed">29258646</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao T.S., Du J., Sun D.P., Zhu Q.R., Chen L.Y., Ye C., Wang S., Liu Y.Q., Cui F., Lu Q.B. A review and meta-analysis of the epidemiology and clinical presentation of coxsackievirus A6 causing hand-foot-mouth disease in China and global implications. Rev. Med. Virol. 2020;30:e2087. doi: 10.1002/rmv.2087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2087</ArticleId><ArticleId IdType="pubmed">31811676</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S.L., Pan H., Liu P., Amer S., Chan T.C., Zhan J., Huo X., Liu Y., Teng Z., Wang L., et al. Comparative epidemiology and virology of fatal and nonfatal cases of hand, foot and mouth disease in mainland China from 2008 to 2014. Rev. Med. Virol. 2015;25:115–128. doi: 10.1002/rmv.1827.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.1827</ArticleId><ArticleId IdType="pubmed">25704797</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S.M., Liu C.C. Enterovirus 71: Epidemiology, pathogenesis and management. Expert. Rev. Anti Infect. Ther. 2009;7:735–742. doi: 10.1586/eri.09.45.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/eri.09.45</ArticleId><ArticleId IdType="pubmed">19681701</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S., Ohka S., Fujii K., Koike S. Functional comparison of SCARB2 and PSGL1 as receptors for enterovirus 71. J. Virol. 2013;87:3335–3347. doi: 10.1128/JVI.02070-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02070-12</ArticleId><ArticleId IdType="pmc">PMC3592140</ArticleId><ArticleId IdType="pubmed">23302872</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Y., Zhang C., Wang H., Zhou G., Wang X., Zhang R., Chen S., Ren J., Chen L., Dang D., et al. Mast cells contribute to Enterovirus 71 infection-induced pulmonary edema in neonatal mice. Lab. Investg. 2018;98:1039–1051. doi: 10.1038/s41374-018-0075-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41374-018-0075-y</ArticleId><ArticleId IdType="pubmed">29765110</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C., Chen S., Zhou G., Jin Y., Zhang R., Yang H., Xi Y., Ren J., Duan G. Involvement of the renin-angiotensin system in the progression of severe hand-foot-and-mouth disease. PLoS ONE. 2018;13:e0197861. doi: 10.1371/journal.pone.0197861.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0197861</ArticleId><ArticleId IdType="pmc">PMC5965884</ArticleId><ArticleId IdType="pubmed">29791486</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Zhu Z., Yang W., Ren J., Tan X., Wang Y., Mao N., Xu S., Zhu S., Cui A., et al. An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of hand foot and mouth disease in Fuyang city of China. Virol. J. 2010;7:94. doi: 10.1186/1743-422X-7-94.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-7-94</ArticleId><ArticleId IdType="pmc">PMC2885340</ArticleId><ArticleId IdType="pubmed">20459851</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing W., Liao Q., Viboud C., Zhang J., Sun J., Wu J.T., Chang Z., Liu F., Fang V.J., Zheng Y., et al. Hand, foot, and mouth disease in China, 2008–2012: An epidemiological study. Lancet Infect. Dis. 2014;14:308–318. doi: 10.1016/S1473-3099(13)70342-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(13)70342-6</ArticleId><ArticleId IdType="pmc">PMC4035015</ArticleId><ArticleId IdType="pubmed">24485991</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R., Liu L., Mo Z., Wang X., Xia J., Liang Z., Zhang Y., Li Y., Mao Q., Wang J., et al. An inactivated enterovirus 71 vaccine in healthy children. N. Engl. J. Med. 2014;370:829–837. doi: 10.1056/NEJMoa1303224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1303224</ArticleId><ArticleId IdType="pubmed">24571755</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F., Xu W., Xia J., Liang Z., Liu Y., Zhang X., Tan X., Wang L., Mao Q., Wu J., et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N. Engl. J. Med. 2014;370:818–828. doi: 10.1056/NEJMoa1304923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1304923</ArticleId><ArticleId IdType="pubmed">24571754</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F.C., Meng F.Y., Li J.X., Li X.L., Mao Q.Y., Tao H., Zhang Y.T., Yao X., Chu K., Chen Q.H., et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2013;381:2024–2032. doi: 10.1016/S0140-6736(13)61049-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)61049-1</ArticleId><ArticleId IdType="pubmed">23726161</ArticleId></ArticleIdList></Reference><Reference><Citation>Chinese Centre for Disease Control and Prevention  Technical Guideline on Use of Inactivated Enterovirus 71 Vaccine.  [(accessed on 1 May 2016)]; Available online:  http://www.chinacdc.cn/zxdt/201606/W020160608725047001222.pdf.</Citation></Reference><Reference><Citation>McLean H.Q., Belongia E.A. Influenza Vaccine Effectiveness: New Insights and Challenges. Cold Spring Harb. Perspect. Med. 2021;11:a038315. doi: 10.1101/cshperspect.a038315.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a038315</ArticleId><ArticleId IdType="pmc">PMC8168527</ArticleId><ArticleId IdType="pubmed">31988202</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang S., Liu H., Wu J., Xiao W., Chen S., Qiu S., Duan G., Song H., Zhang R. Effectiveness of BNT162b2 and mRNA-1273 Vaccines against COVID-19 Infection: A Meta-Analysis of Test-Negative Design Studies. Vaccines. 2022;10:469. doi: 10.3390/vaccines10030469.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10030469</ArticleId><ArticleId IdType="pmc">PMC8954872</ArticleId><ArticleId IdType="pubmed">35335101</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz L.M., Halloran M.E., Rowhani-Rahbar A., Neuzil K.M., Victor J.C. Rotavirus vaccine effectiveness in low-income settings: An evaluation of the test-negative design. Vaccine. 2017;35:184–190. doi: 10.1016/j.vaccine.2016.10.077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2016.10.077</ArticleId><ArticleId IdType="pmc">PMC5154240</ArticleId><ArticleId IdType="pubmed">27876198</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson L.A., Jackson M.L., Nelson J.C., Neuzil K.M., Weiss N.S. Evidence of bias in estimates of influenza vaccine effectiveness in seniors. Int. J. Epidemiol. 2006;35:337–344. doi: 10.1093/ije/dyi274.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyi274</ArticleId><ArticleId IdType="pubmed">16368725</ArticleId></ArticleIdList></Reference><Reference><Citation>Foppa I.M., Haber M., Ferdinands J.M., Shay D.K. The case test-negative design for studies of the effectiveness of influenza vaccine. Vaccine. 2013;31:3104–3109. doi: 10.1016/j.vaccine.2013.04.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.04.026</ArticleId><ArticleId IdType="pubmed">23624093</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan X., Zhang L., Ding L., Zhang C., Chen Z., Cheng Y., Wang X., Peng H., Tang X., Ren X., et al. Effectiveness of enterovirus A71 vaccine against pediatric HFMD and disease profile of post-vaccination infection. Vaccine. 2024;42:2317–2325. doi: 10.1016/j.vaccine.2024.02.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2024.02.026</ArticleId><ArticleId IdType="pubmed">38433065</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang L., Wang J., Zhang C., He W., Mo J., Zeng J., Chen M., Tan Y., Ning C. Effectiveness of enterovirus A71 vaccine in severe hand, foot, and mouth disease cases in Guangxi, China. Vaccine. 2020;38:1804–1809. doi: 10.1016/j.vaccine.2019.12.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2019.12.025</ArticleId><ArticleId IdType="pubmed">31892446</ArticleId></ArticleIdList></Reference><Reference><Citation>Page M.J., McKenzie J.E., Bossuyt P.M., Boutron I., Hoffmann T.C., Mulrow C.D., Shamseer L., Tetzlaff J.M., Akl E.A., Brennan S.E., et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n71</ArticleId><ArticleId IdType="pmc">PMC8005924</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId></ArticleIdList></Reference><Reference><Citation>Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur. J. Epidemiol. 2010;25:603–605. doi: 10.1007/s10654-010-9491-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-010-9491-z</ArticleId><ArticleId IdType="pubmed">20652370</ArticleId></ArticleIdList></Reference><Reference><Citation>Biggerstaff B.J., Jackson D. The exact distribution of Cochran’s heterogeneity statistic in one-way random effects meta-analysis. Stat. Med. 2008;27:6093–6110. doi: 10.1002/sim.3428.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.3428</ArticleId><ArticleId IdType="pubmed">18781561</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulinskaya E., Dollinger M.B., Bjørkestøl K. On the moments of Cochran’s Q statistic under the null hypothesis, with application to the meta-analysis of risk difference. Res. Synth. Methods. 2011;2:254–270. doi: 10.1002/jrsm.54.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jrsm.54</ArticleId><ArticleId IdType="pubmed">26061889</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Zhou Y., Cheng Y., Wu P., Zhou C., Cui P., Song C., Liang L., Wang F., Qiu Q., et al. Effectiveness of EV-A71 vaccination in prevention of paediatric hand, foot, and mouth disease associated with EV-A71 virus infection requiring hospitalisation in Henan, China, 2017–2018: A test-negative case-control study. Lancet Child Adolesc. Health. 2019;3:697–704. doi: 10.1016/S2352-4642(19)30185-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-4642(19)30185-3</ArticleId><ArticleId IdType="pmc">PMC8713082</ArticleId><ArticleId IdType="pubmed">31375313</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Z., Huang B. Effectiveness of inactivated enterovirus type 71 vaccine against hand, foot and mouth disease and adverse reactions among 6-35-month-old children. Chin. J. Vaccines Immun. 2022;28:224–228.</Citation></Reference><Reference><Citation>Wang X., An Z., Huo D., Jia L., Li J., Yang Y., Liang Z., Wang Q., Wang H. Enterovirus A71 vaccine effectiveness in preventing enterovirus A71 infection among medically-attended hand, foot, and mouth disease cases, Beijing, China. Hum. Vaccin. Immunother. 2019;15:1183–1190. doi: 10.1080/21645515.2019.1581539.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2019.1581539</ArticleId><ArticleId IdType="pmc">PMC6605830</ArticleId><ArticleId IdType="pubmed">30779680</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Cui J., Liu F., Song Y., Wang Q., Liu Y., Zhang Y., Li Z., Chang Z. Effectiveness of Enterovirus 71 inactivated vaccines against hand, foot, and mouth disease: A test-negative case-control study. Hum. Vaccin. Immunother. 2024;20:2330163. doi: 10.1080/21645515.2024.2330163.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2024.2330163</ArticleId><ArticleId IdType="pmc">PMC10984126</ArticleId><ArticleId IdType="pubmed">38544389</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Wei M., Jin P., Li J., Zhu F. An evaluation of a test-negative design for EV-71 vaccine from a randomized controlled trial. Hum. Vaccin. Immunother. 2021;17:2101–2106. doi: 10.1080/21645515.2020.1859900.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2020.1859900</ArticleId><ArticleId IdType="pmc">PMC8189103</ArticleId><ArticleId IdType="pubmed">33529093</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen L.Z., Fu J., Pan X.J., Liang H., Xie S.Y., Chen Z.P. Post-marketing observation on safety of inactivated enterovirus A71 vaccine (human diploid cell) Chin. J. Prev. Med. 2019;53:258–261. doi: 10.3760/cma.j.issn.0253-9624.2019.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.issn.0253-9624.2019.03.004</ArticleId><ArticleId IdType="pubmed">30841663</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y., Fu J., Pan X.J., Shen L.Z., Liang Z.Z., Chen Y.P., Hu X.S., Lyu H.K., Chen Z.P. Post-marketing safety analysis of inactivated enterovirus A71 vaccines. Chin. J. Prev. Med. 2019;53:262–266. doi: 10.3760/cma.j.issn.0253-9624.2019.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.issn.0253-9624.2019.03.005</ArticleId><ArticleId IdType="pubmed">30841664</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan X., Zhang C., Wang X., Ren X., Peng H., Tang X., Zhang L., Chen Z., Ye Y., Zheng M., et al. Molecular epidemiology and clinical features of hand, foot and mouth disease requiring hospitalization after the use of enterovirus A71 inactivated vaccine in Chengdu, China, 2017-2022: A descriptive study. Emerg. Microbes Infect. 2022;11:2510–2519. doi: 10.1080/22221751.2022.2125346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2022.2125346</ArticleId><ArticleId IdType="pmc">PMC9621254</ArticleId><ArticleId IdType="pubmed">36103331</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng X.-D., Tong Y., Wei Z.-N., Wang L., Mai J.-Y., Wu Y., Luo Z.-Y., Li S., Li M., Wang S., et al. Epidemical and etiological study on hand, foot and mouth disease following EV-A71 vaccination in Xiangyang, China. Sci. Rep. 2020;10:20909. doi: 10.1038/s41598-020-77768-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-77768-7</ArticleId><ArticleId IdType="pmc">PMC7708472</ArticleId><ArticleId IdType="pubmed">33262488</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M., Chen T., Peng J., Luo Y., Du L., Lu Z., He J., Liu C., Gan Q., Ma W., et al. The spatial-temporal distribution and etiological characteristics of hand-foot-and-mouth disease before and after EV─A71 vaccination in Kunming, China, 2017–2020. Sci. Rep. 2022;12:17028. doi: 10.1038/s41598-022-21312-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-21312-2</ArticleId><ArticleId IdType="pmc">PMC9552732</ArticleId><ArticleId IdType="pubmed">36220850</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang L., Jiang H., Tian X., Xia X., Huang T. Epidemiological characteristics of hand, foot, and mouth disease in Yunnan Province, China, 2008–2019. BMC Infect. Dis. 2021;21:751. doi: 10.1186/s12879-021-06462-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-021-06462-4</ArticleId><ArticleId IdType="pmc">PMC8336324</ArticleId><ArticleId IdType="pubmed">34348655</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L., Wang T., Liu X., Fu Y., Zhang S., Chu Q., Nie T., Tu H., Cheng J., Fan Y. Spatial-temporal-demographic and virological changes of hand, foot and mouth disease incidence after vaccination in a vulnerable region of China. BMC Public Health. 2022;22:1468. doi: 10.1186/s12889-022-13860-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-022-13860-z</ArticleId><ArticleId IdType="pmc">PMC9342842</ArticleId><ArticleId IdType="pubmed">35915424</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Jiang L., Zhang C., He W., Tan Y., Ning C. The changes in the epidemiology of hand, foot, and mouth disease after the introduction of the EV-A71 vaccine. Vaccine. 2021;39:3319–3323. doi: 10.1016/j.vaccine.2021.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.05.009</ArticleId><ArticleId IdType="pubmed">33994239</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong J., Liu F., Qi H., Tu W., Ward M.P., Ren M., Zhao Z., Su Q., Huang J., Chen X., et al. Changing epidemiology of hand, foot, and mouth disease in China, 2013-2019: A population-based study. Lancet Reg. Health West Pac. 2022;20:100370. doi: 10.1016/j.lanwpc.2021.100370.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanwpc.2021.100370</ArticleId><ArticleId IdType="pmc">PMC8743221</ArticleId><ArticleId IdType="pubmed">35036978</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu H., Xue M., Wu C., Lu Q., Ding Z., Wang X., Fu T., Yang K., Lin J. Trend of hand, foot, and mouth disease from 2010 to 2021 and estimation of the reduction in enterovirus 71 infection after vaccine use in Zhejiang Province, China. PLoS ONE. 2022;17:e0274421. doi: 10.1371/journal.pone.0274421.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0274421</ArticleId><ArticleId IdType="pmc">PMC9488823</ArticleId><ArticleId IdType="pubmed">36126038</ArticleId></ArticleIdList></Reference><Reference><Citation>Head J.R., Collender P.A., Lewnard J.A., Skaff N.K., Li L., Cheng Q., Baker J.M., Li C., Chen D., Ohringer A., et al. Early Evidence of Inactivated Enterovirus 71 Vaccine Impact against Hand, Foot, and Mouth Disease in a Major Center of Ongoing Transmission in China, 2011–2018: A Longitudinal Surveillance Study. Clin. Infect. Dis. 2020;71:3088–3095. doi: 10.1093/cid/ciz1188.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciz1188</ArticleId><ArticleId IdType="pmc">PMC7819528</ArticleId><ArticleId IdType="pubmed">31879754</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson M.L., Nelson J.C. The test-negative design for estimating influenza vaccine effectiveness. Vaccine. 2013;31:2165–2168. doi: 10.1016/j.vaccine.2013.02.053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.02.053</ArticleId><ArticleId IdType="pubmed">23499601</ArticleId></ArticleIdList></Reference><Reference><Citation>De Serres G., Skowronski D.M., Wu X.W., Ambrose C.S. The test-negative design: Validity, accuracy and precision of vaccine efficacy estimates compared to the gold standard of randomised placebo-controlled clinical trials. Euro. Surveill. 2013;18:20585. doi: 10.2807/1560-7917.ES2013.18.37.20585.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES2013.18.37.20585</ArticleId><ArticleId IdType="pubmed">24079398</ArticleId></ArticleIdList></Reference><Reference><Citation>Orenstein E.W., De Serres G., Haber M.J., Shay D.K., Bridges C.B., Gargiullo P., Orenstein W.A. Methodologic issues regarding the use of three observational study designs to assess influenza vaccine effectiveness. Int. J. Epidemiol. 2007;36:623–631. doi: 10.1093/ije/dym021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dym021</ArticleId><ArticleId IdType="pubmed">17403908</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu W., Zeng G., Hu Y.M., Hu Y.S., Zhang Y., Hu Y.L., Wang Y., Li J.X., Zhu F.C. A comparative analysis of immunogenicity and safety of an enterovirus 71 vaccine between children aged 3–5 years and infants aged 6–35 months. Expert. Rev. Vaccines. 2018;17:257–262. doi: 10.1080/14760584.2018.1430572.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2018.1430572</ArticleId><ArticleId IdType="pubmed">29363365</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan X., Che Y., Wei S., Li S., Zhao Z., Tong Y., Wang L., Gong W., Zhang Y., Zhao Y., et al. Effectiveness and Safety of an Inactivated Enterovirus 71 Vaccine in Children Aged 6–71 Months in a Phase IV Study. Clin. Infect. Dis. 2020;71:2421–2427. doi: 10.1093/cid/ciz1114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciz1114</ArticleId><ArticleId IdType="pubmed">31734699</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong Y., Zhang X., Chen J., Chen W., Wang Z., Li Q., Duan K., Wei S., Yang B., Qian X., et al. Immunogenicity and safety of an enterovirus 71 vaccine in children aged 36–71 months: A double-blind, randomised, similar vaccine-controlled, non-inferiority phase III trial. eClinicalMedicine. 2022;52:101596. doi: 10.1016/j.eclinm.2022.101596.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101596</ArticleId><ArticleId IdType="pmc">PMC9340505</ArticleId><ArticleId IdType="pubmed">35923425</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Gao F., Zeng G., Yang H., Zhu T., Yang S., Meng X., Mao Q., Liu X. Immunogenicity and Safety of Inactivated Enterovirus 71 Vaccine in Children Aged 36–71 Months: A Double-Blind, Randomized, Controlled, Non-inferiority Phase III Trial. J. Pediatric Infect. Dis. Soc. 2021;10:440–447. doi: 10.1093/jpids/piaa129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jpids/piaa129</ArticleId><ArticleId IdType="pubmed">33269798</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji H., Li L., Liu Y., Ge H., Wang X., Hu J., Wu B., Fu J., Zhang Z., Chen X., et al. Seroepidemiology of human enterovirus71 and coxsackievirusA16 in Jiangsu province, China. Virol. J. 2012;9:248. doi: 10.1186/1743-422X-9-248.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-9-248</ArticleId><ArticleId IdType="pmc">PMC3545860</ArticleId><ArticleId IdType="pubmed">23102275</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang B., Wu P., Wu J.T., Lau E.H., Leung G.M., Yu H., Cowling B.J. Seroprevalence of Enterovirus 71 Antibody Among Children in China: A Systematic Review and Meta-analysis. Pediatr. Infect. Dis. J. 2015;34:1399–1406. doi: 10.1097/INF.0000000000000900.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000000900</ArticleId><ArticleId IdType="pmc">PMC4718881</ArticleId><ArticleId IdType="pubmed">26368058</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang H., Zhang Z., Rao Q., Wang X., Wang M., Du T., Tang J., Long S., Zhang J., Luo J., et al. The epidemiological characteristics of enterovirus infection before and after the use of enterovirus 71 inactivated vaccine in Kunming, China. Emerg. Microbes Infect. 2021;10:619–628. doi: 10.1080/22221751.2021.1899772.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2021.1899772</ArticleId><ArticleId IdType="pmc">PMC8018479</ArticleId><ArticleId IdType="pubmed">33682641</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y.F., Jia L.P., Yu F.Y., Liu L.Y., Song Q.W., Dong H.J., Deng J., Qian Y., Zhao L.Q., Deng L., et al. Molecular epidemiology of coxsackievirus A16 circulating in children in Beijing, China from 2010 to 2019. World J. Pediatr. 2021;17:508–516. doi: 10.1007/s12519-021-00451-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12519-021-00451-y</ArticleId><ArticleId IdType="pmc">PMC8523403</ArticleId><ArticleId IdType="pubmed">34453285</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Liu H., Cao Z., Xu J., Guo J., Zhao L., Wang R., Xu Y., Gao R., Gao L., et al. Epidemiology of Hand, Foot, and Mouth Disease and Genetic Evolutionary Characteristics of Coxsackievirus A10 in Taiyuan City, Shanxi Province from 2016 to 2020. Viruses. 2023;15:694. doi: 10.3390/v15030694.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15030694</ArticleId><ArticleId IdType="pmc">PMC10052898</ArticleId><ArticleId IdType="pubmed">36992403</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomba Ngangas S., Bisseux M., Jugie G., Lambert C., Cohen R., Werner A., Archimbaud C., Henquell C., Mirand A., Bailly J.L. Coxsackievirus A6 Recombinant Subclades D3/A and D3/H Were Predominant in Hand-Foot-And-Mouth Disease Outbreaks in the Paediatric Population, France, 2010-2018. Viruses. 2022;14:1078. doi: 10.3390/v14051078.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14051078</ArticleId><ArticleId IdType="pmc">PMC9144281</ArticleId><ArticleId IdType="pubmed">35632819</ArticleId></ArticleIdList></Reference><Reference><Citation>Carmona R.C.C., Machado B.C., Reis F.C., Jorge A.M.V., Cilli A., Dias A.M.N., Morais D.R., Leme L., Yu A.L.F., Silva M.R., et al. Hand, foot, and mouth disease outbreak by Coxsackievirus A6 during COVID-19 pandemic in 2021, São Paulo, Brazil. J. Clin. Virol. 2022;154:105245. doi: 10.1016/j.jcv.2022.105245.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2022.105245</ArticleId><ArticleId IdType="pmc">PMC9301960</ArticleId><ArticleId IdType="pubmed">35896051</ArticleId></ArticleIdList></Reference><Reference><Citation>Du Z., Huang Y., Bloom M.S., Zhang Z., Yang Z., Lu J., Xu J., Hao Y. Assessing the vaccine effectiveness for hand, foot, and mouth disease in Guangzhou, China: A time-series analysis. Hum. Vaccin. Immunother. 2021;17:217–223. doi: 10.1080/21645515.2020.1763076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2020.1763076</ArticleId><ArticleId IdType="pmc">PMC7872061</ArticleId><ArticleId IdType="pubmed">32530733</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi L., Zhao H., Wu D. Modelling and analysis of HFMD with the effects of vaccination, contaminated environments and quarantine in mainland China. Math. Biosci. Eng. 2018;16:474–500. doi: 10.3934/mbe.2019022.</Citation><ArticleIdList><ArticleId IdType="doi">10.3934/mbe.2019022</ArticleId><ArticleId IdType="pubmed">30674128</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao Y., Jiang Q., Huo X., Yu L., Yang J., Zhao H., Li D., Xu X., Jiang G., Zhang C., et al. Preclinical safety evaluation of a bivalent inactivated EV71-CA16 vaccine in mice immunized intradermally. Hum. Vaccin. Immunother. 2023;19:2209472. doi: 10.1080/21645515.2023.2209472.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2023.2209472</ArticleId><ArticleId IdType="pmc">PMC10208166</ArticleId><ArticleId IdType="pubmed">37217189</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu D., Leung K., Jit M., Yu H., Yang J., Liao Q., Liu F., Zheng Y., Wu J.T. Cost-effectiveness of bivalent versus monovalent vaccines against hand, foot and mouth disease. Clin. Microbiol. Infect. 2020;26:373–380. doi: 10.1016/j.cmi.2019.06.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2019.06.029</ArticleId><ArticleId IdType="pmc">PMC6942242</ArticleId><ArticleId IdType="pubmed">31279839</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W., Dai W., Zhang C., Zhou Y., Xiong P., Wang S., Ye X., Liu Q., Zhou D., Huang Z. A virus-like particle-based tetravalent vaccine for hand, foot, and mouth disease elicits broad and balanced protective immunity. Emerg. Microbes Infect. 2018;7:94. doi: 10.1038/s41426-018-0094-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41426-018-0094-1</ArticleId><ArticleId IdType="pmc">PMC5959873</ArticleId><ArticleId IdType="pubmed">29777102</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X., Chang S., Wang R., Xiao Y., Li F., Xu Q., Zhang S., Chen X., Zhang S., Zhang M., et al. Immunogenicity and Safety of an Inactivated Enterovirus 71 Vaccine Administered Simultaneously with Hepatitis B Virus Vaccine, Group A Meningococcal Polysaccharide Vaccine, Measles-Rubella Combined Vaccine and Japanese Encephalitis Vaccine: A Multi-Center, Randomized, Controlled Clinical Trial in China. Vaccines. 2022;10:895. doi: 10.3390/vaccines10060895.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10060895</ArticleId><ArticleId IdType="pmc">PMC9230521</ArticleId><ArticleId IdType="pubmed">35746502</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Xiao Y., Ye Y., Jiang F., He H., Luo L., Chen H., Shi L., Mu Q., Chen W., et al. Immunogenicity and safety of an inactivated enterovirus 71 vaccine coadministered with trivalent split-virion inactivated influenza vaccine: A phase 4, multicenter, randomized, controlled trial in China. Front. Immunol. 2022;13:1080408. doi: 10.3389/fimmu.2022.1080408.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1080408</ArticleId><ArticleId IdType="pmc">PMC9772018</ArticleId><ArticleId IdType="pubmed">36569946</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>